Sareum Share Discussion Threads

[criticalthinker1] 20/11/2024 21:33

Celtic it's 1802 that was proven to be a worthwhile ipr re lupus...as in differentcategoryof treatments...but indirectly you are correct because the toxicology trials purports to both 1801 snd 1802...and the change in corporate objectives re toxicology criteria means the fact we never met our critical point in its arena amongst global 'leaders' ...and we have a once a day pill formulation given its credence with attributes with criteria of phosphorylation with certain lipids that have crossed membranes they were not supposed to...

I came to this company for a reason. I'm convinced of that. Multiple individuals have stood strong.

Its not about the money. Its about realising the novel expertise here. It is quite extraordinary.

All best Steadydanny 👌

[criticalthinker1] 20/11/2024 20:59

And anyone....anyone ...want to talk about b cell lymphoma and lupus....

Well here you go

Lupus and lymphoma
It is believed that the elevated risk of lymphoma results from the disease process of lupus—specifically the overstimulation of B-cells coupled with defects in the immune system's surveillance system—and not just from medications or other associated risk factors.

Penny will drop soon.

SOG makes great posts on lse as does Krone and Citizen...but oh my if they did their research beyond certain papers that are backed by the pharma companies then the world would wake up with the platform they have.

Off for a few days. Best to all.
Hope people just looking in look at everything.
All best Steadydanny 👌

[criticalthinker1] 20/11/2024 20:50

Has the handbrake been put on Sareum...you tell me...

7 Oct 2021 10:42

RNS Number : 3573O
Sareum Holdings PLC
07 October 2021

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

US Patent Granted for Sareum's SDC-1802 TYK2/JAK1 Inhibitor

Cambridge, UK, 7 October 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that, further to its announcement of 30 July 2021, the United States Patent and Trademark Office has now formally approved its patent in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the "SDC-1802 Programme").

The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development.

Sareum's CSO, Dr John Reader, commented:

"We are pleased to confirm the grant of this US patent for SDC-1802, adding another layer of protection around this promising candidate in key territories. Our SDC-1802 programme is in preclinical development currently and we are designing the translational studies needed to define the optimal cancer application prior to completing toxicology and manufacturing studies. We look forward to providing further updates on progress as we achieve key milestones."

[criticalthinker1] 20/11/2024 20:29

Appreciate HBDs post but this was known nearly 4 years ago...check out what Thoth was saying...I spoke privately with him albeit our public disagreements on lse but he agreed about the points I made. This was part of a converse on lse Jan 2021
albei Ahfam who got ousted as well from lse...but on the same hymn sheet...hence the recent patent approvals

RE: Il-610 Jan 2021 14:55
I'll second that Thoth- This is from the research update in July in regards Lupus US Army studies-

'Specifically, it was reported that treatment with TYK2/JAK1 inhibitor SAR-20351 (now known as SDC-1802) reduces autoantibodies (biological markers of lupus severity) in a spontaneous mouse model of SLE. The data also provided evidence that SAR-20351 inhibits cytokines that play a critical role in lupus, including interferon-alpha, IL-6 and IL-23. The inhibition of IL-23 signalling by SAR-20351 may play a role in the decrease of autoantibodies in the lupus mouse model, as IL-23 signalling drives the differentiation of Th17 cells, which leads to autoantibody production and are pathogenic in lupus'.

Big pharmas hold the gold and push it back with trolls ...noteabley on ADVFN...but thankfully they have gone...made a point to the domain owner...and they respected my point.

I think the board are getting payback from the big pharma who screwed them.
Large lady is warming her tonsils.
The facts (imo) is the lies die and the real treatments come to fruition.
All best Steadydanny

[criticalthinker1] 18/11/2024 22:58

Check out the latest Tucker podcast.
Effectively JFK Jr is going to rip apart the destruction of novel drug development.

[criticalthinker1] 16/11/2024 19:34

So HBD On lse says that the website offering 1801 is not actually available...and this from the site

For this product's availability, delivery time and price, please email [e-mail] directly or click the "Inquiry Now" button below.

All best.

[criticalthinker1] 16/11/2024 16:29

I appreciate Feargs post on lse.
I also acknowledge that my posts are sometimes a bit cryptic. So Fearg I doubt you are alone in not quite understanding my rambles.
In response I confess my posts could be better explained.
My reasoning for the way I post is that a bit of frustration leads to my posts content, but also that I feel that if I posted exactly what I have in my continuous research that what I want to post has been met with ridicule.
I believe that is changing.

Very best regards and I note SOGs post re the ability to purchase 1801

I wonder what part of the accounts released by Sareum purveys to production of 1801 and sales?...Surely there is some due diligence and legal protocols required re any external house trials.

Interesting times and very best to all.

[criticalthinker1] 15/11/2024 19:10

And those who know knew well before!

The big pharmas need novel IPR!

Specifically ones that deal with cytokine storms re certain interleukins.

Good weekend to all.

[criticalthinker1] 15/11/2024 18:55

So certain Pharmas are hemorrhaging value. What's the common link.
Love reading the liberals on GSK LSE stating Trump is a problem re appointment of RFKjr.
The gravy train of pushing their monies into the organisations that give the accreditation is over.
Saw this 6 months ago and served me well...saw the main issue back in 2019.
Our time is coming!
Cytokine storms!
Cytotoxicity!
Turbo Cancers!
...so much more I could say
And if you are still sceptical check out the interview on youtube with John Campbell interviewing Clare Craig..very recent!....
And then the another interview with the one who has since been appointed to support RFKjr.
You want to know why Sareum were nearly stuffed?
Listen to the interviews and consider what got pushed and what got pushed aside.
I'm pretty sure Shepherd Dollar had his opinion for increasing his investment...maybe he is on the same hymn sheet.
Our day ...s..are overdue

[criticalthinker1] 15/11/2024 06:43

Some interesting links to Sareum and its ipr.

Long term holders will know about Galapagos....Gilead.....and Biofocus DPI.
Which then has links to Sierra Oncology...then GSK....and full circle to Boundless Bio.

All best.

[criticalthinker1] 14/11/2024 19:01

Fierce Pharma 13.11.24 extract...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in acquiring external products with the potential to launch in the near term. Meanwhile, those pharmas facing greater generic threats in the coming decade may be more inclined to pick up earlier-stage candidates from beyond their own pipelines.

That’s according to a new report from Leerink Partners outlining large pharma companies’ loss of exclusivity (LOE) exposure between both 2025 and 2030, and 2030 through 2040.

Note the part about needing earlier stage developments. There are numerous big pharmas who need real development drugs....not just rehashed old drugs!!!! to put a plug in their rapidly declining MCs....note GSK are down some 25% in the last 6 months and dosnt look like it's going to stop. They need NOVEL DRUG DEVELOPMENT.


I sincerely believe the board are in a very strong position re their ipr and cash position at this very moment in time! And it has never been in a better position IMO!
Their trial change decision makes perfect sense to me.

I also sincerely believe that they are putting us on the 'bio-pharma catwalk' and that multiple companies are very interested.

Also imo the voluptuous lady is warming her tonsils to serenade us...

Best regards to all genuine investors

Steadydanny

[criticalthinker1] 12/11/2024 06:50

Given the shift in geopolitics I believe we will see certain promising research areas coming back into the attention of the 'important' science.

Imo don't write off the results Sareum got regards ARDS treatment!
There are growing respected scientific voices being heard after being pushed aside for 'other' questionable focusing...which was questionably backed by corporate funding without proper due diligence.
Below is an extract of an area 1801 excelled in...we know the rest..

The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor.

Don't be surprised if a positive curve ball appears that shines the light on Sareum and its ipr.

Best regards Steadydanny

[criticalthinker1] 08/11/2024 19:29

Blimey it's quite a tough thing posting here knowing the assaults coming but I still stand proud of my research and position that the members of Sareum are on the end game ..plus a bit..

[criticalthinker1] 08/11/2024 17:18

So Potnak reports citizen for a neutral post....
Can we all see the agenda of potnak now!?

[norma_stitts] 07/11/2024 18:49

DeAar, leave the lying to Wooftah, it’s got the market covered on that. It’s the only thing it excels at, so let it have its glory! 👍

[countbruga] 07/11/2024 14:26

Keep trying. What are you going to call me next? Surfie?